Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: Pharmacokinetic and clinical considerations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 8, 2013, Pages 1015-1024

  Müller, Thomas ^a  

^a St Joseph Hospital Berlin Weissensee   (Germany)

Author keywords

Adenosine; Dopamine substitution; Homocysteine; Istradefylline; l dopa; Monoamine oxidase; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; ISTRADEFYLLINE; LEVODOPA; METHYLXANTHINE; MONOAMINE OXIDASE B INHIBITOR; PARAXANTHINE; PRELADENANT; ST 1535; THEOPHYLLINE; TOZADENANT; UNCLASSIFIED DRUG; VIPADENANT;

ARTICLE; BEHAVIOR; BEHAVIOR CHANGE; CLINICAL FEATURE; DIZZINESS; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DYSKINESIA; EDEMA; FATIGUE; HUMAN; INSOMNIA; METABOLIC DISORDER; METABOLISM; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSIS; QT PROLONGATION; RECEPTOR AFFINITY; SIDE EFFECT;

ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DYSKINESIAS; HALF-LIFE; HUMANS; LEVODOPA; PARKINSON DISEASE; PURINES; TREATMENT OUTCOME;

EID: 84880337603     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.795541     Document Type: Article

References (53)

1. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: Conceptual aspects. J Neural Transm 2004;111(2):201-16
2. Riederer P, Gerlach M, Muller T, Reichmann H. Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007;13(8):466-79
3. Ekesbo A, Rydin E, Torstenson R, et al. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999;52(1):120-5
4. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors. Neurology 2000;55(11 Suppl 4):S72-7
5. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology 2002;59(3):408-13
6. Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010;7(2):203-24
7. Calabresi P, Di FM, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008;23(Suppl 3):S570-9
8. Muller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 2006;7(13):1715-30
9. Muller T. Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert Opin Drug Metab Toxicol 2011;7(7):847-55
10. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-23
11. Gottwald MD, Aminoff MJ. New frontiers in the pharmacological management of Parkinson's disease. Drugs Today (Barc) 2008;44(7):531-45
12. Waters C. Other pharmacological treatments for motor complications and dyskinesias. Mov Disord 2005;20(Suppl 11):S38-44
13. Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004;11(15):2033-43
14. Clarke CE. Rasagiline for motor complications in Parkinson's disease. Lancet 2005;365(9463):914-16
15. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21(8):677-92
16. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
17. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 2011;18(12):1373-8
18. Muller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113(10):1441-8
19. Muller T, Erdmann C, Muhlack S, et al. Inhibition of catechol- Omethyltransferase contributes to more stable levodopa plasma levels. Mov Disord 2006;21(3):332-6
20. Bibbiani F, Oh JD, Kielaite A, et al. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 2005;196(2):422-9
21. Del DP, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study. Mov Disord 2001;16(3):515-20
22. Verhagen ML, Del DP, van den MP, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50(5):1323-6
23. Fox SH, Lang AE, Brotchie JM. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. Mov Disord 2006;21(10):1578-94
24. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-86
25. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23(5):700-7
26. Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003;184(1):285-94
27. Grondin R, Bedard PJ, Hadj TA, et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52(8):1673-7
28. Spinnewyn B, Charnet C, Cornet S, et al. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats. Fundam Clin Pharmacol 2011;25(5):608-18
29. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A)receptor antagonist treatment of Parkinson's disease. Neurology 2003;61(3):293-6
30. Chen JF, Fredduzzi S, Bastia E, et al. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson's disease. Neurology 2003;61(11 Suppl 6):S74-81
31. Xiao D, Bastia E, Xu YH, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 2006;26(52):13548-55
32. Chase TN, Bibbiani F, Bara-Jimenez W, et al. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003;61(11 Suppl 6):S107-11
33. Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: Rationale, therapeutic potential and clinical experience. Drugs Aging 2005;22(6):471-82
34. Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson's disease: What's next? Curr Neurol Neurosci Rep 2012;12(4):376-85
35. Weiss SM, Benwell K, Cliffe IA, et al. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 2003;61(11 Suppl 6):S101-6
36. Yang M, Soohoo D, Soelaiman S, et al. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 2007;375(2):133-44
37. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A)receptor antagonist istradefylline in advanced PD. Neurology 2003;61(3):297-303
38. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23(15):2177-85
39. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63(3):295-302
40. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70(23):2233-40
41. Factor S, Mark MH, Watts R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord 2010;16(6):423-6
42. Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study. Mov Disord 2010;25(10):1437-43
43. Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010;16(1):16-20
44. Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13(1):111-14
45. Salamone JD, Betz AJ, Ishiwari K, et al. Tremorolytic effects of adenosine A2A antagonists: Implications for parkinsonism. Front Biosci 2008;13:3594-605
46. Salamone JD, Farrar AM, Font L, et al. Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behav Brain Res 2009;201(1):216-22
47. Bleickardt CJ, Lashomb AL, Merkel CE, Hodgson RA. Adenosine A(2A) receptor antagonists do not disrupt rodent prepulse inhibition: An improved side effect profile in the treatment of Parkinson's disease. Parkinsons Dis 2012;2012:591094
48. Labeaume P, Dong M, Sitkovsky M, et al. An efficient route to xanthine based A(2A) adenosine receptor antagonists and functional derivatives. Org Biomol Chem 2010;8(18):4155-7
49. Müller T. The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson's disease. Clin Med Insights Ther 2010;2:155-68
50. Pedata F, Pugliese AM, Melani A, Gianfriddo M. A2A receptors in neuroprotection of dopaminergic neurons. Neurology 2003;61(11 Suppl 6):S49-50
51. Pierri M, Vaudano E, Sager T, Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005;48(4):517-24
52. Szabo N, Kincses ZT, Vecsei L. Novel therapy in Parkinson's disease: Adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol 2011;7(4):441-55
53. Przuntek H, Conrad B, Dichgans J, et al. SELEDO: A 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999;6(2):141-50